Back

Assessment of TIMI frame count pre- and post- intracoronary acetylcholine administration in patients with angina and non-obstructive coronary arteries (ANOCA)

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Physiology matters: pushing the boundaries of invasive functional assessment applications Coronary Vasoreactivity Testing ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mrs Helen Holdermann

Robert Bosch Hospital, Stuttgart (Germany)

7 More presentations in this session

Presentation thumbnail
Cycling coupled to intra-coronary thermodilution to evaluate angina with non-obstructive coronary artery disease
Doctor G. Rahoual (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Safety and feasibility of nationwide invasive coronary function testing in patients with angina and no obstructive coronary artery disease (NL-CFT).
Ms C. Crooijmans (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Intracoronary nicardipine to induce hypaeremia
Doctor T. Mahendiran (Aalst, BE)
Abstract Slides Video
Presentation thumbnail
Absolute coronary flow and microvascular resistance before and after TAVR
Doctor E. Gallinoro (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Comparison of adenosine, dobutamine and bicycle exercise on intracoronary physiological indices in patients with myocardial bridges
Doctor A. Sinha (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Physiology matters: pushing the boundaries of invasive functional assessment applications

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Coronary slow flow as measured by corrected TIMI frame counts is associated with impaired microvascular resistance
thumbnail
Congress Presentation
Coronary physiology: no complete diagnosis without acteylcholine
thumbnail
Congress Presentation
Cycling coupled to intra-coronary thermodilution to evaluate angina with non-obstructive coronary artery disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources